Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

Abstract
Signaling pathways that converge on two different transcription factor complexes, NFκB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen.